← Back
Data updated: Jun 28, 2026
KAMAT
Pharma Pharmaceuticals
KAMAT is a pharmaceutical company with 1 FDA-approved products.
2024
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules
KAMAT's Key Drugs
KAMAT's core commercial portfolio centers on RALDESY — its most strategically important drugs approved in the last 15 years.
KAMAT's Recent FDA Approvals
KAMAT secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
KAMAT's Therapeutic Areas
Disease areas where KAMAT has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
KAMAT Pipeline Snapshot
Active clinical trials for KAMAT across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RALDESY leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-11-26
- Latest
- 2025-11-13
- Applications
- 1